NICE

Resource impact template

Resource impact Published: 18 October 2023

www.nice.org.uk

NICE has produced a <u>resource impact template</u> that incorporates the following technology appraisal guidance for axial spondyloarthritis:

- <u>Tofacitinib for treating active ankylosing spondylitis</u> (2023) NICE technology appraisal guidance 920
- <u>Bimekizumab for treating axial spondyloarthritis</u> (2023) NICE technology appraisal guidance 918
- <u>Upadacitinib for treating active non-radiographic axial spondyloarthritis</u> (2023) NICE technology appraisal guidance 861
- <u>Upadacitinib for treating active ankylosing spondylitis</u> (2022) NICE technology appraisal guidance 829
- <u>Secukinumab for treating non-radiographic axial spondyloarthritis</u> (2021) NICE technology appraisal guidance 719
- <u>Ixekizumab for treating axial spondyloarthritis</u> (2021) NICE technology appraisal guidance 718